CN Patent

CN121443286A — 用于治疗神经障碍的组合物

Assigned to Map Light Therapy Co ltd · Expires 2026-01-30 · 0y expired

What this patent protects

描述了用于治疗神经障碍(诸如精神分裂症、阿尔茨海默病精神病、帕金森病精神病、阿尔茨海默病中的认知、路易体痴呆中的精神病、双相障碍和运动障碍)的化合物1和非索罗定的联合组合物。

USPTO Abstract

描述了用于治疗神经障碍(诸如精神分裂症、阿尔茨海默病精神病、帕金森病精神病、阿尔茨海默病中的认知、路易体痴呆中的精神病、双相障碍和运动障碍)的化合物1和非索罗定的联合组合物。

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: CN121443286A
Jurisdiction: CN
Classification: —
Expires: 2026-01-30
Drug substance claim: No
Drug product claim: No
Assignee: Map Light Therapy Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.